Crossmark

: S.M. received a research grant to their institution from Recordati Rare Diseases; is a consultant to Novo Nordisk and Crinetics. L.d.F. received a research grant to his institution from Abiogen Pharma S.p.A. M.F. received grants to their institution from Amryt, Crinetics, Ionis and Recordati Rare Diseases, received occasional consulting fees or has served as occasional advisory board member for Amryt, Crinetics, Camurus, Ipsen and Recordati Rare Diseases. N.K. has been a speaker for Pfizer, Ipsen and Recordati Rare Diseases, investigator for Pfizer and Ipsen and scientific advisory board for Pfizer, Ipsen and Recordati Rare Diseases. M.G. has received speakers honoraria from Ipsen and Pfizer. R.S. has been a consultant for Lundbeck, Amryt, Novo Nordisk, Camurus, Ascendis and Crinetics. S.T. has received honoraria, lecture and advisory fees and grants from Crinetics, Novartis, Strongbridge, HRA Pharma and Recordati Rare Diseases. P.M. has been a principal investigator in clinical trials of Ipsen, Pfizer and Camurus, received consultation fee and research support from Pfizer and Recordati Rare Diseases. E.B.G. is an investigator for research grants to MSKCC from Chiesi and Recordati Rare Diseases, consultant to Crinetics, Recordati and Chiesi. L.K. is on the advisory board for Novo Nordisk, Recordati Rare Diseases and Camurus and has received research support from Camarus. A.J.v.d.L. has received consulting and speaking fees from Amolyt Pharma and Pfizer. J.B. has received speakers fee from Novartis, Ipsen and Pfizer and unrestricted research grants from Novartis and Ipsen. D.E. has received lecture fees from Ipsen, Pfizer and Recordati Rare Diseases. S.M.W. is on scientific advisory boards for Novartis, Ipsen, Pfizer, Lilly, Strongbridge, Shire, Crinetics, Recordati Rare Diseases and HRA and has received speaker fees from Ipsen, HRA, Recordati Rare Diseases and Consilient Health, unrestricted research funds from Novartis, Ipsen, Pfizer and HRA and participated in clinical trials of Novartis, Recordati Rare Diseases and Cortendo. E.V. is on the advisory board for Recordati Rare Diseases and HRA Pharma, received speaker fees from Recordati Rare Diseases, HRA Pharma and Ipsen. S.N. has received consulting, research and speaking fees from Novo Nordisk, Crinetics, Recordati Rare Diseases and Pfizer. P.C. has received unrestricted research and educational grants from Ipsen, Recordati Rare Diseases, Advanz and Pfizer, is an investigator (principal or coordinator) for clinical trials funded by Chiasma, Recordati Rare Diseases, Pfizer, Crinetics and Debiopharm, is a member of advisory boards for Pfizer, Crinetics, Recordati Rare Diseases and Amolyt, lectures for Ipsen, Recordati Rare Diseases and Pfizer. A.G.I. occasionally consults for Crinetics, Camurus and Xeris, has received research grants to their institution from Recordati Rare Diseases, Xeris and Chiesi. B.M.K.B. is a principal investigator of an institutional grant from Crinetics and occasional consultant to Amolyt, Amryt, Camurus, Crinetics and Recordati Rare Diseases. S.L.S. is principal investigator for Chiasma (Chiesi) and Pasireotide (Novartis, now Recordati Rare Diseases). K.S. has received honoraria for consulting, speaking and scientific projects from the following companies: Pfizer, Recordati Rare Diseases, Camurus, Crinetics, Novo Nordisk and Ascendis. I.S. has received consulting and lecture fees from Pfizer, Medison Pharma, Novo Nordisk and OPKO Biologics and participated in clinical studies by Crinetics and Debiopharm. C.L.B. has received speaking fees from Ipsen, consulting fees from Ipsen, Recordati Rare Diseases and Novo Nordisk and is a principal investigator of clinical trials of Crinetics. A.C. is a principal investigator of research studies for Novartis, Ipsen and Pfizer, a consultant for Novartis, Ipsen and Pfizer, received honoraria from Novartis, Ipsen and Pfizer. P.K. participated in clinical trials of Carmus and Recordati Rare Diseases. S.F. has received consultancy and speaker fees from Ipsen and Pfizer, consultancy fee from Novartis, is an advisory board member for Recordati Rare Diseases and Novo Nordisk and has received grants to their institution from Abiogen Pharma S.p.A. S.C. has received lecture and advisory fees and grants from Ipsen and Recordati Rare Diseases. S.P. has been a speaker at workshops and/or an advisory board member for HRA Pharma, Ipsen, Lilly, Novo Nordisk, Pfizer and Recordati Rare Diseases. M.R.G. has received speaker fees from Recordati Rare Diseases, Ipsen and Novo Nordisk, is a member of the advisory board of Recordati Rare Diseases, Ipsen, Novo Nordisk and Crinetics, is principal investigator in clinical trials from Recordati Rare Diseases and Crinetics. M.P.-D. received funding for advisory board or lectures given at symposia organized by Recordati Rare Diseases, Pfizer, Novartis and Ipsen. A.L. has received lecture fees from Ipsen and served as consultant for Novo Nordisk. T.B. is clinical trial investigator for Xeris, Crinetics, Debiopharm and Recordati Rare Diseases, is on advisory boards for Pfizer, Recordati Rare Diseases and Novo Nordisk, received speaker fees from Pfizer, Recordati Rare Diseases, Novo Nordisk and received research grants from Pfizer. D.F. received fees for lecture and advisory boards from Novartis, Camurus and Recordati Rare Diseases. Y.G. participated in clinical trials of Crinetics, Cortendo, Debiopharm and Ascendis. C.J.S. is an advisory board member or recipient of speaker’s fees from Novo Nordisk, Amolyt, Pfizer, Crinetics, Sandoz-Hexal, Recordati Rare Diseases, Debiopharm and Consilient Health. A.G. is a consultant for Amolyt, Ipsen, Pfizer and Recordati Rare Diseases. The other authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below